Our Technologies:
Translating Breakthrough Science Into Real-World Solutions
At Bioramics, we specialize in advancing extraordinary biotechnologies from early-stage discoveries to market-ready solutions. Our pipeline showcases a portfolio of revolutionary products—each powered by our proprietary Time-Released Ion Matrix (TRIM) platform and supported by our rigorous development framework. These innovations are not incremental improvements—they are first-in-class breakthroughs designed to fill critical gaps in treatment, recovery, and care.
Every technology in our pipeline is the product of deep scientific collaboration, exclusive intellectual property licensing, and our proven platform model that de-risks and prepares innovations for commercial acquisition. Whether it's improving the quality of life for patients with muscular dystrophy, accelerating muscle recovery in animals, or enabling targeted delivery in regenerative medicine, Bioramics is building the future of biotech—one asset at a time.
Explore the pipeline below to learn more about our three current flagship products—each unique, unprecedented, and ready to transform its respective market.
DystropHix is a first-of-its-kind bio-ceramic injectable therapy developed to significantly improve muscle strength and mobility in individuals with muscular dystrophy. Unlike gene therapies that target a small subset of patients, DystropHix is safe, non-systemic, and designed to benefit the entire MD population. Backed by FDA Rare Pediatric Disease and Orphan Drug designations, it represents a scalable, accessible, and life-enhancing solution poised to reshape the standard of care in neuromuscular disease.
Anaramics is an innovative injectable compound that accelerates muscle repair and recovery in non-consumable animals such as performance horses and working dogs. With no known adverse effects and a unique mechanism that speeds healing by enhancing blood vessel growth, Anaramics is the only product of its kind. Stable, easy to administer, and ready for commercial sale, it offers immediate impact for the global animal health market.
SCRM Bio is a next-generation stem cell delivery device designed to overcome one of the greatest challenges in regenerative medicine—targeted, sustained, and effective cell placement. Built on a proprietary bio-ceramic matrix, it delivers stem cells precisely to sites of tissue damage, supporting optimal engraftment and healing. By enhancing how therapies are delivered at the cellular level, SCRM Bio has the potential to revolutionize treatment protocols and usher in a new era of precision medicine for surgeons, researchers, and clinicians alike.